PIDOTIMOD IN TREATMENT OF RECURRENT PHARYNGOTONSILLITIS

Abstract

In order to assess the efficacy of two immunostimulant treatments for prevention of recurrent pharyngotonsillitis, a controlled, parallel group clinical study was conducted. 40 subjects, adults and children, with a positive history of at least acute, febrile, infectious episodes in the oropharyingeal region, were randomized to treatment with pidotimod or with lyophilized polybacterial lysates (LPL). 90 days after the start of treatment, the pidotimod group showed a significant in crease in multitest response by comparison to the LPL group. During the observation period, moreover, a significantly lower incidence of infectious episodes was seen in the pidotimod group than in the LPL group. Tolerance and compliance were good for both drugs.Key word: recurrent pharyngotonsillitis, pidotimod, treatment.